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Abstract
Background: Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data
are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in
early therapy escalation.
Objective: To investigate the safety and efficacy of off-label treatment with rituximab in an MS-cohort
of predominantly de novo patients or as therapy escalation.
Methods:We retrieved safety and efficacy data from the Norwegian MS-registry and biobank for all MS-
patients treated with rituximab at Haukeland University Hospital, Bergen, Norway, during a four year
period.
Results: In the 365 MS-patients (320 relapsing-remitting MS (RRMS), 23 secondary progressive MS
(SPMS), and 22 primary progressive MS (PPMS)), the overall annualized relapse rate (ARR) was 0.03
and annualized drug discontinuation rate (ADDR) was 0.05. NEDA-3 was achived in 79% of patients
with available data (n¼351). Sixty-one patients experienced infusion-related adverse events of which
two were serious (CTCAE grade 3–4). Eighteen patients experienced serious non-infusion related
adverse events, of which 16 were infections. Infections (n¼ 34; 9.3%, CTCAE grade 2-5), hypogam-
maglobulinemia (n ¼ 19, 5.2%) and neutropenia (n¼ 16; 4.4%) were the most common non-infusion-
related adverse events.
Conclusion: Rituximab was a safe and highly efficient disease modifying therapy in this cohort of MS-
patients; however, infections and neutropenia need to be monitored.
Keywords: Rituximab, multiple sclerosis, treatment response, efficacy, adverse effects, disease modi-
fying therapies
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Introduction
Increasing evidence suggests that B-cell depletion is
a safe and highly effective therapy option in multiple
sclerosis (MS).1 More than a decade ago, the
first randomized, controlled phase II trial of an
anti-CD20-antibody (rituximab) demonstrated high
efficacy in MS.2 Rituximab was not included in fur-
ther development programs in relapsing-remitting
MS (RRMS), but the humanized monoclonal anti-
CD20-antibody ocrelizumab has recently proved
effective in phase II/III trials, both in RRMS and
primary progressive MS (PPMS).3,4 Emerging real
world data indicate a comparable and possibly supe-
rior effect and tolerability of rituximab compared to
other standard MS-treatments.5–12
Rituximab has to a large extent been used as a last-
resort MS-treatment, but high efficacy treatments are
now more frequently used at an early disease stage.
At Haukeland University Hospital, Western Norway,
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rituximab has been the preferred therapeutic option
for highly active MS in treatment naive patients
since 2016, as well as an equivalent option for ther-
apy switch or escalation in MS. Hence, rituximab
has become the most commonly used MS-
immunomodulatory therapy at our hospital. Based
on the experience from this treatment approach, we
conducted a retrospective cohort study to describe
safety and efficacy of rituximab therapy in MS
patients at Haukeland University Hospital during
2015–2019.
Material and methods
This study was a single-centre, retrospective cohort
study of all MS-patients who initiated rituximab
therapy from 01.01.15 until 01.01.19 and consented
to registration in the National MS registry at the
Department of Neurology, Haukeland University
Hospital, Bergen, Norway. Patients were identified
through the Norwegian MS registry and cross-
checked with the Department’s list of patients
treated with rituximab. From 2016 rituximab
became the drug of choice for highly active disease
both in therapy escalation and in treatment naı̈ve
patients, i.e. patients with two or more of the follow-
ing characteristics: young age, severe function loss
or extensive MRI-lesions. Observation time was set
from the date of treatment initiation (at latest
01.01.19) until 01.07.19 if rituximab was not discon-
tinued. If patients discontinued rituximab, observa-
tion time was set until six months after the latest
rituximab infusion, or the date of initiation of a
new disease modifying therapy (DMT).
Study variables
Data were retrieved from the Norwegian MS
Registry and biobank and included age, sex, date
of disease onset, number of relapses in total and
during the last two years prior to rituximab therapy,
previous treatment, and reason for initiation or
switch to rituximab. Efficacy recording included
date of any relapse or new magnetic resonance imag-
ing (MRI) T1 gadolinium henhancing (T1Gdþ)
lesion, or new T2 lesion, and change in Kurtzke
Expanded Disability Status Scale (EDSS) from base-
line to latest observation, at least sixmonths from
rituximab initiation. Safety recording included date
and reason for rituximab discontinuation, and
adverse events.
Treatment regimen and monitoring
The majority of patients received a single infusion of
rituximab 1000mg intravenously (i.v.) at initiation,
followed by 500mg i.v. every 6months. Patients
who started rituximab treatment between
01.01.2015-31.12.2016 normally received a dose of
total 2000mg i.v. at initiation (given as two single
infusions of 1000mg i.v. within an interval of
twoweeks) followed by 500mg i.v. every sixmonths
(Table 1).
MRI scans were performed on 1.5 T or 3 T scanners.
The most recent MRI before rituximab initiation was
defined as the baseline MRI scan. A re-baseline scan




Rituximab i.v. 1000mg at 0 days, 500mg every 6months
(Patients initiating treatment between
01.01.2015 and 31.12.2016: 1000mg at
0 days, 1000mg at 14 days, 500mg every
6months.)
Paracetamol p.o. Premedication with an antipyretic (paracetamol
1000mg tablet) approximately 30-60minutes
prior to each infusion.
Cetirizine p.o. Premedication with an antihistamine (cetirizine
10mg tablet) approximately 30-60minutes
prior to each infusion;
Methylprednisolone i.v. Premedication with 125mg intravenous meth-
ylprednisolone approximately 30minutes
prior to each infusion
In case of infusion reactions:
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was planned 6months after rituximab treatment ini-
tiation, followed by a new MRI scan at 12months,
and further every 12months, or if clinically indicat-
ed. Brain MRI scan was performed routinely, and a
spinal MRI scan was performed if clinically indicat-
ed. An EDSS was planned as part of clinical evalu-
ation in the outpatient clinic at latest sixmonths after
rituximab initiation, and at regular follow-up every
6–12months. Laboratory tests including hemoglobin
(Hb), white blood cells with differential count, plate-
let count, ESR (erythrocyte sedimentation rate),
CRP (C-reactive protein), liver function parameters
(GGT (Gamma-Glutamyl Transferase), ALT (ala-
nine transaminase, AST (Aspartate transaminase),
ALP (alkaline phosphatase)), kidney function (creat-
inine), IgG and IgM (immunoglobuline G and M)
were performed every 6 months.
Study outcomes
Efficacy outcomes included (i) annual relapse rate,
(ii) number of patients experiencing new MRI-
disease activity during observation, defined as new
T2 or T1Gdþ lesions, and (iii) disability progres-
sion, measured as change in EDSS (0.5 points or
more), and (iv) proportion of patients with no evi-
dence of disease activity (NEDA-3). NEDA-3 was
defined as a composite score comprising absence of
clinical relapses and disability progression, in addi-
tion to no new MRI disease activity (new T1Gdþ or
new/enlarging T2-lesions) on MRI examinations for
the given period. Treatment outcomes were evaluat-
ed for the period before the re-baseline MRI (i.e. the
first sixmonths of therapy) and after the re-baseline
MRI (i.e. >sixmonths of therapy). Safety outcomes
included all reported adverse events, including
infusion-related adverse events, except mild infec-
tions (Common Terminology Criteria for adverse
events (CTCAE) grade 1), which were not included
due to suspected incomplete registration in the reg-
istry and patient records.
Statistical methods
Survival (relapse-free survival, MRI event-free sur-
vival, progression free survival) was estimated with
Kaplan–Meier survival curves. Analyses were per-
formed in SPSS version 24 (IBM Corp., Armonk,
NY). Descriptive data were described as means,
medians and percentages.
Approval and patient consent
All data were retrieved from the Norwegian MS
Registry and biobank, where participants have
given a prospective informed consent. The study
was approved of by Regional Committee for




A total of 365 MS-patients (320 RRMS, 23 SPMS,
22 PPMS) who initiated disease modifying treatment
in Haukeland University Hospital, Department of
neurology with rituximab during the predefined
study period, and consented to registration in the
Norwegian MS registry, were included. One patient
(n¼1, RRMS) was identified through the
Department’s list of patients but had refused consent
to the registry and was not included. Table 2 presents
baseline characteristics. Mean (SD) age was 42.3 (
12.2) years and median (range) disease duration was
5.3 ( 7) years at rituximab initiation. Mean obser-
vation time was 610 days (277).
About one third of the patients (n¼ 126; 34.5%)
were treatment naı̈ve, either newly diagnosed
(within the last 2months (n¼ 104, 28.5%)) or
never received DMT (n¼ 22, 6.0%). The rest were
switched from different interferon beta preparations
(n¼ 12; 3.3%), glatiramer acetate (n¼ 11; 3.0%),
teriflunomide (n¼ 49; 13.4%), dimethyl fumarate
(n¼ 47; 12.9%), natalizumab (n¼ 42; 11.5%),
alemtuzumab (n¼ 6; 1.6%), fingolimod (n¼ 48;
13.2%), other (mycophenolate, n ¼ 2, 0.5%) or
haematopoetic stem cell transplantation (HSCT)
(n¼ 2; 0.5%), or did at the moment not receive
DMT (n¼ 20, 5.5%). Treatment failure was the
most common reason for swithching from another
DMT (n¼ 98; 26.8%).In patients receiving no treat-
ment (n ¼ 42), disease progression was the most
common reason for initiating rituximab (n¼ 38;
10.4%).
Treatment response
Relapse rate, frequency of new MRI lesions, EDSS
change and drug discontinuation rate were calculat-
ed and are all displayed in Table 3.
Observation time for patients in the study was <12
months in 74 patients, and 12 months in 291
patients. In 133 patients, observation time was 24
months.
Clinical relapses. The overall annualized relapse
rate (ARR) in this cohort was 0.03 (RRMS 0.03,
SPMS 0.03, PPMS 0). During the first sixmonths
of treatment, fourteen patients experienced a relapse
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of treatment or more, seven patients experienced a
relapse and two had a further relapse. When exclud-
ing observation time and early relapses <6months
of treatment, with the intention of looking at treat-
ment effect after 6months, ARR was calculated to
0.02. In two patients, repeated relapses or a relapse
after sixmonths of treatment was the reason for drug
discontinuation.
In patients switching to rituximab after HSCT
(n¼2), new relapses occurred in one.
Subgroup analyses. ARR for the subgroup receiving
an initial dosage of 2000mg (1000mgþ 1000mg)
was 0.05 (n¼ 44), and 0.02 for an initial dosage of
1000mg (n¼ 321).
ARR in the subgroup of newly diagnosed patients
was 0.02 (n¼ 104), and 0.03 in other patients
(n¼ 219) during study observation time.
MRI lesions. One or more control MRIs during rit-
uximab treatment were available for 358 patients
(98%). New or enhanced MRI-lesions occurred in
58 patients (n¼ 52 in RRMS, n¼ 4 in SPMS, n¼ 2
in PPMS). When excluding MRI events before
sixmonths of treatment, 17 patients experienced
new or enhanced MRI lesions. In nine of these, no
early MRI scan (<6months) after rituximab initia-
tion was available.
Two patients discontinued rituximab due to treat-
ment failure; both experienced relapses and more
than one MRI event.
Table 3. Treatment response and discontinuation in MS patients receiving rituximab.
Subgroups
Total (365)RRMS (320) SPMS (23) PPMS (22)
Relapses during observation, n 15 1 0 16
– Relapses occuring after 6months, n 8 1 0 9
Annual relapse rate (ARR) 0.03 0.03 0 0.03
– ARR calculated for observation
time and relapses occuring after 6months
0.02 0.04 0 0.02
Patients with any new or enhanced
MRI- lesions, n
52 4 2 58
– Patients with new or enhanced
MRI- lesions 6months
13 3 1 17
EDSS change, median (range) 0 (3.0 2.5) 0 (0.0 – 2.0) 0 (1,0 – 1.5) 0 (–3.0 – 2.5)
– Improved EDSS, n (%) 18 (5.7%) 0 1 (4.5%) 19 (5.4%)
– Stable EDSS, n, % 282 (89.8%) 16 (72.7%) 18 (81.8%) 316 (89.8%)
– Worsened EDSS, n, % 10 (3.2%) 6 (27.3%) 1 (4.5%) 17 (4.6%)
NEDA-3 at end of observation, n (%) 80.3% 57.1% 81.0% 79.0%
Drug discontinuation, n (%)









Reason for discontinuation, n (% of total)
– Treatment failure 1 1 0 2 (0.5%)
– Adverse events 13 3 2 18 (4.9%)
– Patient’s request of HSCT 4 2 0 6 (1.6%)
– Patient’s request of discontinuation 4 1 1 6 (1.6%)
– Other 1 0 0 1 (0.3%)
Figure 1. Change in EDSS during rituximab treatment in
the 361 patients with at least two EDSS-evaluations.
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Disability progression. EDSS was available at base-
line and after at least 6months of treatment for 352
patients (96%). In 316 (89.8%) patients EDSS was
unchanged between their first and last available
score. In RRMS patients, EDSS improved in 18
(5.7%), and worsened in ten (3.2%) patients. In
the progressive disease subgroup, EDSS improved
in one (3.4%) and worsened in seven (16.7%)
patients. In progressive disease courses, observation
time was less than a year in 13 patients, 1-2 years in
32 patients, and  2 years in 13 patients. Figure 1
displays change in EDSS related to MS subgroup.
NEDA (no evidence of disease activity). NEDA- 3
was available for calculation in 351 patients. 279 of
351 (79%) patients with available data fulfilled the
criteria for NEDA-3 (no new MRI lesions, no EDSS
progression or clinical relapses) throughout their
observation time in this study.
Drug survival. Treatment was discontinued in 33
(9%) patients, resulting in an annual drug discontin-
uation rate (ADDR) of 0.05 (RRMS 0.04, SPMS
0.20, PPMS 0.10). The most frequent reason for dis-
continuation was adverse events (n¼ 18, 4.9%,
CTCAE grade 1–2 in 14 cases, grade 3–4 in 4
cases). In two patients (0.5%), discontinuation was
due to treatment failure (new MRI-lesions and clin-
ical relapses). Six patients (1.1%) requested rituxi-
mab discontinuation in order to receive HSCT
abroad. Figure 2 demonstrates MRI event-free sur-
vival, relapse-free survival and drug survival on rit-
uximab during observation time.
Safety. Safety data results are displayed in Table 4.
118 patients (32.3%) experienced a total of 156 reg-
istered adverse events.
Infusion-related adverse events (CTCAE grade 1-5)
were registered in 61 patients (16.7%). All were
Figure 2. Disease activity free (MRI and relapses) patients and treatment continuation in 355 MS-patients receiving
rituximab treatment.
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mild (CTCAE grade 1-2) except 2 cases (CTCAE
grade 3): One patient reported a rash and a unilateral,
mild facial paresis 30-60min after infusion, which
resolved spontaneousely within hospital admission
the next 60minutes. One patient experienced an
acute generalized rash and dyspnoea during infusion,
which resolved after peroral antihistamine. Both were
admitted to hospital. Rituximab was continued with no
further serious infusion-related adverse events.
Among non-infusion-related adverse events, 18
(5.0%) were serious (CTCAE grade 3–4). The
majority (n¼ 16) were infections; Urosepsis
(n¼ 3), diverticulitis (n¼ 2), neutropenic fever
(n¼ 2), pneumonia (n¼ 3), pansinusitis (n¼ 1), cho-
lecystitis (n¼ 1), spondylodiscitis (n¼ 1), neoerli-
chiosis (tick-borne infection) (n¼ 1), enteritis
(n¼ 1) and proctitis (n¼ 1). The rate of infections,
excluding mild cases not requiring any medical
treatment or doctor’s visit (CTCAE grade 1), was
17.4% in SPMS, 8.7% in RRMS and 9.1% in
PPMS patients.
One patient died during the study observation time;
cause of death was suicide, considered not to be
related to rituximab treatment. Two patients were
diagnosed with malignant disease (colon cancer,
melanoma) during observation time, both were diag-
nosed after rituximab initiation, and both discontin-
ued rituximab treatment. No case of progressive
multifocal leukoencephalopathy (PML) was
recorded.
Neutropenia (count< 1.5 109/L) during rituximab
treatment with no other known cause was recorded
in 16 (4.3%) patients. 6 patients experienced
Table 4. Safety and adverse events in MS-patients receiving rituximab therapy.
Subgroups
RRMS (320) SPMS (23) PPMS (22) Total (365)
Patients who experienced any adverse event, n
(%)
105 (32.8%) 8 (34.8%) 5 (22.7%) 118 (32.3%)
Number of adverse events, n 142 6 8 156
Patients who experienced any infusion-related
adverse event (CTCAE grade 1-5), n (%)
56 (17.5%) 2 (8.7%) 3 (13.6%) 61 (16.7%)
– Serious infusion-related events (CTCAE
grade 3–4), n (%) 2 (0.6%) 0 0 2 (0.5%)
Patients who experienced any serious non-
infusion-related adverse events (CTCAE
grade 3–4), n (%)
13 (4.1%) 4 (17.0%) 1 (4.5%) 18 (4.9%)
– Serious infections 11 (3.4%) 4 (17.0%) 1 (4.5% 16 (4.4%)
– Other serious non-infusion related adverse
events (ventricular extrasystoles, tinnitus)
2 (0.5%) 0 0 2 (0.5%)
Patients registered with any infection (CTCAE
grade 2–5), n (%)
28 (8.7%) 4 (17.4%) 2 (9.1%) 34 (9.3%)
Deaths (CTCAE grade 5), n 0 1a 0 1a
PML cases, n 0 0 0 0
Patients receiving cancer diagnosis during
observation period, n
0 0 2b 2b
Patients with neutropenia, n (%) 14 (4.4%) 0 2 (9.1%) 16 (4.4%)
 Neutrophil count 0,5 – 1.0 109/L (CTCAE
grade 3)
2 (0.6%) 0 0 2 (0.5%)
 Neutrophil count <0.5 109/L (CTCAE
grade 4)
3 (0.9%) 0 1 (4.5%) 4 (1.1%)
Other laboratory parameters:Patients with
hypogammaglobulinemia (IgG) of any grade
, n (%)





moderate or severe neutropenia (count <1,0 x 109/L)
and expressed the following characteristics: All six
patients had neutrophil count and leucocyte counts
within normal range at baseline (within 2 weeks
before rituximab initiation). One had experienced
neutropenia earlier, which resolved. Five out of six
were< 40 years of age. 1 patient had PPMS and
EDSS > 6, the remaining had RRMS with EDSS
0-2. None had relevant comorbidities. Earlier treat-
ment included HSCT (n¼ 1) and dimetylfumarat
(n¼ 2), the remaining were treatment naı̈ve
(n¼ 3). Total number of rituximab infusions were
2–4; 1 patient had received an initial dose of
2000mg rituximab. Two neutropene patients were
admitted to hospital with febrile neutropenia, both
were treated with i.v. antibiotics. One was admitted
to hospital with a suspected fungal infection and
received treatment with G-CSF (Granulocyte
Colony Stimulating Factor). Three patients had no
symptoms and neutrophile count normalized within
1-4weeks. All patients recovered fully, but rituxi-
mab was discontinued in two cases due to recurrent
neutropenia and high age, respectively.
Subgroup analyses. In patients with neutropenia (n
¼ 16), 5 patients were registered with any infection
as an adverse event. In patients without neutropenina
(n¼349), 31 patients were registered with an
infection.
In patients receiving an initial dose of rituximab of
2000mg, 3/44 (6.8%) were registered with any
infection (CTCAE grade 2–5) versus 31/321
(9.7%) in patients receiving regular dose (1000
mg) at rituximab initiation, and 2/44 (4.5%) were
registered with neutropenia versus 14/321 (4.4%) in
patiens receiving regular dose at initiation. 6/44
(13.6%) patients who received 2000 mg rituximab
at initiation were registered with hypogammaglobu-
linemia (low IgG) at any time during observation,
compared to 13/321 (4.0%) in the group who
received a regular dose at initiation.
Discussion
We present one of the largest cohorts of MS-patients
treated with rituximab to date, utilizing real world
data from the Norwegian MS Registry.
Efficacy data are in line with results from several
studies of similar design6,8,12 including a larger
cohort study of similar design and study popula-
tion.10 Another large, recent multicentric
observational study reported similar results; one
difference to notice is the higher proportion of
treatment naive patients in our cohort, pointing to
the differences in therapeutic approach and patient
selection in reported off-label MS-treatment with
rituximab. Our cohort includes a relatively high pro-
portion (28.5%) of newly diagnosed patients starting
rituximab as their first choice DMT compared to
many studies based on real-world data.
The overall ARR of 0.03 was low, and so was the
ARR of 0.02 calculated in >6months of treatment,
when assuming a transient initial periode of subop-
timal treatment effect. The calculated ARR for
patients receiving a higher starting dose of rituximab
was 0.05; this subgroup of patients also started treat-
ment earlier (2015-2016) while rituximab was not
concidered a first choice treatment, and could possi-
bly represent a subgroup with more persistent dis-
ease activity in the cohort.
The total number of patients with new MRI lesions
was lowafter initiation of rituximab, and after
>6months of treatment. A large proportion of
patients starting rituximab had a recent history of dis-
ease activity (newly diagnosed patients, recent treat-
ment failure on other DMTs, recent disease
progression without ongoing therapy), which
strengthens the efficacy results and indicate low
inflammatory disease activity during rituximab treat-
ment, further underlined by the low proportion of
patients discontinuing treatment, and a very low pro-
portion of patients discontinuing rituximab due to
new disease activity.
EDSS was mainly unchanged during rituximab treat-
ment. Notably, the baseline EDSS score might have
been transiently worsened in some patients at ritux-
imab initiation due to recent relapses, which could
lead to overestimation of improvement in EDSS
during treatment. EDSS was recorded during regular
clinical follow up and a validation of change in
EDSS score was not demanded in the study design.
We recorded a clinically significant number of
patients in progressive disease courses registered
with EDSS progression during rituximab treatment
(7 out of 44 in SPMS and PPMS with valid EDSS
scores). This is in line with previous studies reporting
that disability progression may be reduced, but not
completely stopped, during rituximab or ocrelizumab
treatment in progressive MS disease courses.4,14 For
progressive disease courses, the observation time was
relatively short, and the number of patients (n¼ 45)
was low, which limits further conclusions.
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One of the main goals was to evaluate safety of
rituximab treatment in MS. The rates of adverse
events and the main categories of side effects in
this cohort were comparable to those seen in popu-
lations of rheumatological and other autoimmune
diseases.15,16 Among serious adverse events, infec-
tions was the most common, corroborating a recent
report from a Swedish MS-population.17 Moderate
and severe neutropenia (count <1.0 x 10 9) was seen
in 1.6% of patients in this cohort and may represent
a serious risk to the patient’s health. As neutrophil
counts were registered only at baseline and every
6months, we could not estimate the onset time of
neutropenia or the full extent. Late onset neutropenia
is a well-known side effect of rituximab treatment18
but has only been documented in few MS-patients
treated with rituximab in retrospective studies.19,20
Our results indicate that neutropenia may be under-
reported if not monitored.
The present study has several strengths. As a single-
centre study, the treatment- and observation protocol
was standardized, and all safety data and clinical
records were fully available. Thus, serious adverse
events should be well monitored and recorded,
including laboratory monitoring and all hospitaliza-
tions, though recording of mild adverse events offer
challenges. The dosing regimen in this cohort was
largely homogenous, only a few patients (12.1%)
received a higher initial dosing, and almost 90%
of the patients receiving the regular maintenance
dose regimen with no postponed doses. The study
population included a relatively high proportion of
treatment naive patients, contributing novel data for
this subgroup. An important limitation of the present
study is the retrospective, uncontrolled design, with-
out adjustments for possibly confounding factors.
The relatively short observation time, especially in
progressive disease, is another limitation, and a con-
trol group would have strengthened the study.
Our data indicate that rituximab is a safe and highly
effective treatment option in MS, both as first-line
and escalation therapy. The extent of treatment with
rituximab is still limited, most likely because it is
off-label therapy, and because of the lack of phase
III treatment study documentation. Systematic safety
documentation is therefore important. Infections,
including serious infections, seem to represent an
important safety issue during rituximab therapy in
MS, and the frequency of both mild and severe neu-
tropenia could be underestimated as there is a lack of
knowledge about onset time, and patients might be
asymptomatic. Further studies should focus on
treatment naive patients, and also how to prevent
infections through improved screening or adjusted
dosing or dosing intervals.
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